Wang R, Yuan Q, Wen Y, Zhang Y, Hu Y, Wang S
Mini Rev Med Chem. 2024; 24(21):1930-1939.
PMID: 38716553
DOI: 10.2174/0113895575295976240415045602.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J
Int J Mol Sci. 2024; 25(5).
PMID: 38473776
PMC: 10931797.
DOI: 10.3390/ijms25052529.
Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Zhao L, Iwanaga R
Biology (Basel). 2023; 12(12).
PMID: 38132337
PMC: 10740672.
DOI: 10.3390/biology12121511.
Pitts S, Laiho M
Cancers (Basel). 2022; 14(23).
PMID: 36497261
PMC: 9737084.
DOI: 10.3390/cancers14235776.
Farooq U, Notani D
Front Cell Dev Biol. 2022; 10:948351.
PMID: 36158211
PMC: 9500187.
DOI: 10.3389/fcell.2022.948351.
It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy.
Kung C, Weber J
Front Cell Dev Biol. 2022; 10:818744.
PMID: 35155432
PMC: 8833255.
DOI: 10.3389/fcell.2022.818744.
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.
Miles X, Vandevoorde C, Hunter A, Bolcaen J
Front Oncol. 2021; 11:703442.
PMID: 34307171
PMC: 8296304.
DOI: 10.3389/fonc.2021.703442.
A wild-derived inbred mouse strain, MSM/Ms, provides insights into novel skin tumor susceptibility genes.
Okumura K, Saito M, Wakabayashi Y
Exp Anim. 2021; 70(3):272-283.
PMID: 33776021
PMC: 8390311.
DOI: 10.1538/expanim.21-0017.
Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2 complex.
Zhang W, Li L, Cai L, Liang Y, Xu J, Liu Y
Cell Death Differ. 2021; 28(6):1926-1940.
PMID: 33504946
PMC: 8184998.
DOI: 10.1038/s41418-020-00724-5.
Non-Canonical Functions of the ARF Tumor Suppressor in Development and Tumorigenesis.
Lagopati N, Belogiannis K, Angelopoulou A, Papaspyropoulos A, Gorgoulis V
Biomolecules. 2021; 11(1).
PMID: 33445626
PMC: 7827855.
DOI: 10.3390/biom11010086.
Survival of Lung Cancer Patients Dependent on the LOH Status for , , and .
Fry E, Niehans G, Kratzke R, Kai F, Inoue K
Int J Mol Sci. 2020; 21(21).
PMID: 33120969
PMC: 7662351.
DOI: 10.3390/ijms21217971.
Identification of Germline Mutations in Melanoma Patients with Early Onset, Double Primary Tumors, or Family Cancer History by NGS Analysis of 217 Genes.
Stolarova L, Jelinkova S, Storchova R, Machackova E, Zemankova P, Vocka M
Biomedicines. 2020; 8(10).
PMID: 33050356
PMC: 7601281.
DOI: 10.3390/biomedicines8100404.
NPM1 exhibits structural and dynamic heterogeneity upon phase separation with the p14ARF tumor suppressor.
Gibbs E, Perrone B, Hassan A, Kummerle R, Kriwacki R
J Magn Reson. 2019; 310:106646.
PMID: 31751897
PMC: 6934896.
DOI: 10.1016/j.jmr.2019.106646.
Dual Role of the Alternative Reading Frame ARF Protein in Cancer.
Fontana R, Ranieri M, La Mantia G, Vivo M
Biomolecules. 2019; 9(3).
PMID: 30836703
PMC: 6468759.
DOI: 10.3390/biom9030087.
Aberrant Expression of p14 in Human Cancers: A New Biomarker?.
Inoue K, Fry E
Tumor Microenviron. 2019; 1(2):37-44.
PMID: 30740529
PMC: 6364748.
DOI: 10.4103/tme.tme_24_17.
The Role of RNA Editing in Cancer Development and Metabolic Disorders.
Kung C, Maggi Jr L, Weber J
Front Endocrinol (Lausanne). 2019; 9:762.
PMID: 30619092
PMC: 6305585.
DOI: 10.3389/fendo.2018.00762.
c-MYB and DMTF1 in Cancer.
Fry E, Inoue K
Cancer Invest. 2019; 37(1):46-65.
PMID: 30599775
PMC: 6431554.
DOI: 10.1080/07357907.2018.1550090.
Translocations involving ETS family proteins in human cancer.
Fry E, Mallakin A, Inoue K
Integr Cancer Sci Ther. 2018; 5(4).
PMID: 30542624
PMC: 6287620.
DOI: 10.15761/ICST.1000281.
Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.
Inoue K, Fry E
Cancer Invest. 2018; 36(9-10):520-536.
PMID: 30396285
PMC: 6500763.
DOI: 10.1080/07357907.2018.1533965.
Aberrant expression of p16 in human cancers - a new biomarker?.
Inoue K, Fry E
Cancer Rep Rev. 2018; 2(2).
PMID: 29951643
PMC: 6018005.
DOI: 10.15761/CRR.1000145.